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Since the adoption of Milan criteria more than 20 years ago, 
selection criteria for liver transplantation (LT) in patients 
suffering from hepatocellular carcinoma (HCC) represented 
a debated issue. Halazun and colleagues presented at the 
American Surgical Association of 2018, and published on 
the issue of October of Annals of Surgery, their results from 
an analysis aimed at including alpha-fetoprotein (AFP) in 
a model developed to predict long-term results after LT 
for HCC (1). Of 1,450 patients included between 2001 
and 2013, 16.2% were outside Milan criteria, 61.1% were 
hepatitis C virus (HCV) positive and more than 80% of 
candidates received pre-LT locoregional therapies. Their 
study showed that incorporating AFP levels at diagnosis, 
maximum AFP (Max-AFP) at any time point, and the 
final immediate pre-transplant AFP (Final-AFP) to tumor 
number and diameter can well stratify different groups 
of patients at different risks of HCC recurrence after LT 
(NYCA model).
The quality of the present study relies on the use of AFP 
as the surrogate of response to pre-LT therapies and this 
latter, in turn, can be considered a biological marker of 
tumor aggressiveness (and vice-versa). As outlined, more 
than 80% of patients underwent some kind of neo-adjuvant 
therapies. However, the assessment of modern mRECIST 
is time consuming and can be subject to disagreement 
between different radiologists (2). In this sense, AFP 
provides a more objective response criteria. This is a 
conceptual improvement in the development of a replicable 
prognostic model in the present clinical scenario. 
However, to fully understand the importance of the 
present study in this specific field it should be briefly 
pointed out what is the already knowledge in regards of 
such predictive models. Authors underlines in their work 
that already developed calculators as Duvoux’s French 
AFP score (3) and Mazzaferro’s Metroticket 2.0 (4) used 
AFP at a single time point, even though patients usually 
wait many months for transplantation during which neo-
adjuvant therapies are commonly administered. Effectively, 
the Duvoux model used AFP level at listing with a median 
waiting time to LT of 4.7 months (3). Nevertheless, taking 
into account tumor features on re-assessment, the French 
AFP model was still able to discriminate patients at high- 
and low-risk of recurrence (3). The Metroticket 2.0 used 
the relationship existing between radiological response 
to neo-adjuvant therapies, being final AFP and pre-LT 
tumor features as determinant of post-LT prognosis (4). 
Consequently, present findings did not significantly improve 
our knowledge. The novelty has to be searched in the fact 
that it was developed in a US cohort, whereas the previous 
two were developed in European countries but most aspects 
were already addressed in such previous literature (3-5). 
However, the present study takes the right road for future 
improvements which should be represented by external 
validation and the adoption of competing-risk analysis. 
In fact, both the model of Duvoux and of Mazzaferro 
were externally validated (2,4), being the Metroticket 
2.0 also validated in an Eastern cohort (2), providing the 
necessary robustness for being used in the clinical setting. 
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The study from Halazun lacks of such external validation, 
which should be planned in the future. Authors claimed 
that the C-statistic for NYCA was significantly superior to 
those of Milan and of the French AFP scores (P<0.001) but 
such comparison can not be considered correct, since before 
comparing C-statistics of different prognostic models an 
independent external validation group must be identified. 
Second, in the present study competing-risk analysis 
was only marginally adopted, correctly assuming death as 
competing to recurrence. This could have been a quality 
of the present work, since 61.1% of patients were HCV+, 
transplanted in an era [2001–2013] burdened by untreatable 
and deadly HCV recurrence. Thus, early death for HCV-
recurrence can mistakenly lead to the conclusion that 
large/multinodular HCCs +/− high AFP levels can be 
safety transplanted simply because the event of interest 
(recurrence) never occurred due to the premature death of 
the patient (6-8). Unfortunately, such quality was restricted 
to a final additional analysis whereas all the study should be 
more robust if Cox was abandoned in favor of competing-
risk (4). To date, only Metroticket 2.0 addressed such a 
clinical complex requisite (4).
In conclusion, in the last decade many efforts have 
been made to build prognostic systems able of improving 
discrimination and calibration of Milan criteria. The two 
more recent are now adults, while the present is still young 
to be applied clinically, but paved the road for future 
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